LA JOLLA, Calif.
Jan. 3, 2013
Regulus Therapeutics Inc
), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that
Kleanthis G. Xanthopoulos
, Ph.D., President and CEO of Regulus, will present a company overview at the 31
Annual J.P. Morgan Healthcare Conference on
Thursday, January 10, 2013
11:30 AM PST
at the Westin St. Francis Hotel in
Garry E. Menzel
, Ph.D., Regulus' Chief Operating Officer and Executive Vice President of Finance, will participate on a panel at the East/West CEO Conference on
Sunday, January 6, 2013
, at the Four Seasons Hotel in
San Francisco, CA.
The J.P. Morgan Healthcare Conference presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at
. A replay of the J.P. Morgan Healthcare Conference webcast will be archived on the Company's website for two weeks following the J.P. Morgan Healthcare Conference presentation.
Regulus Therapeutics Inc. (
) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting
RNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (
) and Isis Pharmaceuticals (
). Regulus is advancing
RNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.